Cadent Therapeutics, a biopharmaceutical company developing novel treatments for patients with movement and cognitive disorders, announced that FDA accepted its IND application for CAD-1883 for the treatment of spinocerebellar ataxia.
CAD-1883 is a first-in-class selective positive allosteric modulator of SK channels (small conductance, calcium-activated potassium ion channels).
Cadent Therapeutics is now looking forward to initiating Phase 2 randomized trial in order to evaluate the safety and efficacy of CAD-1883.
Read more about Cadent Therapeutics here.
Image by Darko Stojanovic from Pixabay
